AFC-HD AMS Life Science (2927) Fundamentals 2026 — P/E 10.3x, Revenue Analysis | SniperIQ
AFC-HD AMS Life Science (2927) is a JP-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥12.5B, trading at ¥861.00 on the JPX. This SniperIQ fundamentals page covers AFC-HD AMS Life Science's valuation (P/E 10.3x, P/B 0.8x), profitability (net margin 3.6%), revenue (¥32.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AFC-HD AMS Life Science's market cap?
AFC-HD AMS Life Science (2927) has a market capitalization of approximately ¥12.5B, trading at ¥861.00 on the JPX. Market cap moves with the live share price.
What is AFC-HD AMS Life Science's P/E ratio?
AFC-HD AMS Life Science's trailing twelve-month P/E ratio is 10.3x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is AFC-HD AMS Life Science?
AFC-HD AMS Life Science runs a net profit margin of 3.6%, a gross margin of 34.2%, and an operating margin of 7.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AFC-HD AMS Life Science generate?
AFC-HD AMS Life Science reported revenue of ¥32.7B for fiscal year 2025, with net income of ¥1.4B and earnings per share (EPS) of 102.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AFC-HD AMS Life Science pay a dividend?
AFC-HD AMS Life Science offers a trailing dividend yield of about 4.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is AFC-HD AMS Life Science financially healthy?
AFC-HD AMS Life Science carries a debt-to-equity ratio of 1.47x and a current ratio of 0.82x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AFC-HD AMS Life Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AFC-HD AMS Life Science (2927) the key facts are: market cap ¥12.5B, P/E 10.3x, revenue ¥32.7B, 52-week range 810-918. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track AFC-HD AMS Life Science's full fundamentals live
Get AFC-HD AMS Life Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.